XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A Strong Growth Candidate Meeting Minervini’s Criteria

XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) has been identified as a high-growth momentum stock that aligns with Mark Minervini’s Trend Template. The company’s technical strength, combined with accelerating fundamentals, makes it a candidate worth examining for growth-oriented investors.

Why XERS Fits the Minervini Trend Template

Minervini’s strategy focuses on stocks exhibiting strong uptrends with improving fundamentals. XERS meets these criteria:

• Price Above Key Moving Averages: The stock trades at $4.75, well above its 50-day ($4.66), 150-day ($4.17), and 200-day ($3.89) moving averages.
• Upward-Trending Averages: The 50-day, 150-day, and 200-day MAs are all rising, confirming sustained momentum.
• Relative Strength: With a ChartMill Relative Strength score of 93.95, XERS outperforms 94% of stocks.
• Price Performance: The stock is up 125% over the past year and remains within 25% of its 52-week high ($6.07).

High Growth Momentum Fundamentals

Beyond technicals, XERS shows strong growth metrics:

• Revenue Growth: Quarterly revenue growth stands at 47.9%, with full-year revenue up 29.9% (TTM).
• Earnings Acceleration: EPS growth surged 57.1% in the latest quarter, following a 70% increase in the prior quarter.
• Analyst Upgrades: EPS estimates for next year have been revised upward by 39.4% over the past three months.
• Consistent Revenue Beats: The company has beaten revenue estimates in all of the last four quarters.

Technical Outlook

The stock is consolidating near recent highs, with support around $4.68. A breakout above $4.90 could signal further upside.

Our High Growth Momentum + Trend Template screener lists more stocks with similar characteristics. For a deeper technical breakdown, review the full technical report on XERS.

Disclaimer

This is not investment advice. Always conduct your own research before making any investment decisions.